EDTXF (Spectral Medical) Dividends Paid

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EDTXF Spectral Medical Inc EDTXF
7 GF Score
Price $0.79
GF Value $0.58
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Spectral Medical Dividends Paid?

Dividends Paid only applicable to companies reporting Cash Flow from Operations in direct method.

EDTXF
7GF Score
Spectral Medical Inc EDTXF
Dividends Paid is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Spectral Medical (EDTXF) Overvalued in 2026?

Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued. The current stock price of $0.79 is trading 36.1% above its estimated GF Value™ of $0.58. GuruFocus considers Spectral Medical to be Significantly Overvalued.

Key valuation signals for EDTXF:

  • Dividends Paid:
  • GF Value™: $0.58 vs. price of $0.79 (36.1% above fair value)
  • GF Score™: 7/100 with 10 warning signs

No single metric tells the full story. See the EDTXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spectral Medical Business Description

Other Exchanges SD4:GermanyEDT:Canada
Address 135 The West Mall, Unit 2, Finance, Toronto, ON, CAN, M9C 1C2
Spectral Medical Inc. is a Canadian medical device and diagnostics company focused on treatments for sepsis and septic shock. Its lead program is the Targeted Polymyxin B Hemoperfusion (PMX) therapy, which uses the Toraymyxin device to remove endotoxins from the bloodstream, paired with its Endotoxin Activity Assay (EAA), a rapid in-vitro diagnostic that measures endotoxin levels in blood to identify patients likely to benefit from the therapy. The company also produces and sells proprietary reagents, including recombinant proteins, antibodies, and calibrators, used in research and diagnostic applications. Spectral Medical generates revenue through product sales of its diagnostic and reagent lines, and it is pursuing regulatory approval and commercialization of its PMX therapy in the United States and other markets. Its customers include hospitals, clinical laboratories, and research organizations. The company is headquartered in Toronto, Canada.
7GF Score

Get the complete analysis for EDTXF

Dividends Paid is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.79
Price
$0.58
GF Value